Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress & Expo

Rhea-AI Summary

Enteris BioPharma, a subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced an accepted abstract for oral presentation at the ASRM 2022 Scientific Congress & Expo from Oct 22-26, 2022, in Anaheim, CA. The abstract focuses on pharmacokinetics of an oral formulation of leuprolide developed using Enteris' Peptelligence® platform, showcasing its efficacy in delivering superior drug levels compared to injectable products. The presentation is set for Oct 26, 2022, at 11:05 AM PT, highlighting advancements in oral administration for better patient compliance, particularly for diseases influenced by GnRH agonists.

Positive

• Acceptance of abstract for presentation at ASRM 2022 showcases Enteris' innovative approach.
• Oral formulation of leuprolide demonstrates superior pharmacokinetic properties compared to injectables.
• Potential for improved patient compliance and address significant medical needs.

Negative

• None.

BOONTON, N.J., July 14, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced today an abstract has been accepted for an oral presentation at the ASRM 2022 Scientific Congress & Expo being held Oct. 22-26, 2022 in Anaheim, Calif The abstract highlights research into the pharmacokinetics of an oral formulation of leuprolide developed utilizing Enteris' proprietary Peptelligence^® platform, a novel formulation technology that enables oral delivery of molecules that are typically injected, including peptides and BCS class III and IV small molecules.

The American Society for Reproductive Medicine's conference will feature experts in reproductive endocrinology and infertility, genetics, male reproduction, access to care and practice management among other topics.

"We are looking forward to presenting our findings at ASRM 2022 highlighting the pharmacokinetic properties of Enteris' oral tablet formulation of leuprolide and its ability to achieve drug levels exceeding those of approved injectable leuprolide products," said Enteris Chief Medical Officer Dr. Gary Shangold. "Oral administration of leuprolide offers the potential to better address diseases in which gonadotropin-releasing hormone (GnRH) agonists are known to provide benefit and for which an oral format can improve patient compliance. Women are disproportionately impacted by such diseases, and we believe access to next-generation treatments, such as oral leuprolide, are increasingly needed."

The title of the abstract follows:

Title:	Pharmacokinetic (PK) Study of Oral Leuprolide Delivery with Ovarest® Achieves Drug Levels Exceeding those of Approved Injectable Products
Author(s):	Gary A. Shangold M.D., Arkady Rubin PhD, Thomas Daggs, John Vrettos PhD, Andrejs Rasums, Angelo Consalvo, Nicola Skeet, Sreeja Variam, Kalpana Ramakrishnan PhD, and Paul Shields PhD

 

The in-person presentation will at the ASRM Scientific Congress & Expo at the Anaheim Convention Center on Oct 26, 2022, 11:05 AM Pacific Time. The program for "ASRM 2022: Genes, Gametes, and Genetics" may be accessed at https://www.asrm.org/globalassets/asrm/asrm-content/events/2022-congress/2022-preliminary-program.pdf.

About Enteris BioPharma
Enteris BioPharma, Inc. is a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH) offering total integrated contract development and manufacturing (CDMO) services including innovative formulation solutions utilizing its proprietary drug delivery technologies, Peptelligence^® and ProPerma®. The technologies have been the subject of numerous feasibility studies and active development programs, several of which are in clinical development. Additionally, Enteris BioPharma is advancing an innovative internal product pipeline of drug products that address significant unmet clinical needs for which there is no satisfactory treatment option. For more information on Enteris BioPharma and its proprietary oral drug delivery technologies, please visit http://www.EnterisBioPharma.com.

View original content:https://www.prnewswire.com/news-releases/enteris-biopharma-announces-acceptance-of-abstract-for-oral-presentation-at-asrm-2022-scientific-congress--expo-301586515.html

SOURCE Enteris BioPharma, Inc.

FAQ

What is the significance of the ASRM 2022 presentation for SWKH?

The ASRM 2022 presentation highlights Enteris BioPharma's advancements in drug delivery, potentially benefiting SWKH's market position and investor interest.

When will the oral presentation on leuprolide take place?

The oral presentation on leuprolide will occur on October 26, 2022, at 11:05 AM Pacific Time.

What technology does Enteris use for the oral formulation of leuprolide?

Enteris employs its proprietary Peptelligence® platform to develop the oral formulation of leuprolide.

How does the oral formulation of leuprolide compare to injectables?

The oral formulation achieves drug levels exceeding those of approved injectable leuprolide products, offering potential advantages in treatment efficacy.

What are the implications of the oral leuprolide formulation for patient care?

The oral formulation could enhance patient compliance by providing a less invasive treatment option for conditions treated with GnRH agonists.